Related Experiment Videos
[Laboratory and clinical studies of sulbactam/ampicillin in pediatric field]
T Nishimura1, K Tabuki, S Aoki
1Department of Pediatrics, Osaka Medical College.
Insights
This study evaluated sulbactam/ampicillin (SBT/ABPC) in pediatric bacterial infections. The combination antibiotic demonstrated high efficacy and a favorable safety profile in clinical trials.
Area of Science:
- Pharmacology and Therapeutics
- Pediatric Infectious Diseases
Context:
- Bacterial infections in children pose a significant public health challenge.
- The development of effective and safe antimicrobial agents is crucial for pediatric care.
- Sulbactam/ampicillin (SBT/ABPC) is a combination antibiotic with a broad spectrum of activity.
Purpose:
- To assess the pharmacokinetic properties of sulbactam/ampicillin (SBT/ABPC) in pediatric patients.
- To evaluate the clinical efficacy and safety of SBT/ABPC in treating various pediatric bacterial infections.
Summary:
- Laboratory and clinical studies were conducted on sulbactam/ampicillin (SBT/ABPC).
- Pharmacokinetic analysis showed dose-dependent serum levels and half-lives following intravenous administration.
- Clinical treatment of 21 pediatric bacterial infections (including tonsillitis, bronchitis, pneumonia) resulted in excellent or good outcomes in all cases, with minimal side effects.
Impact:
- Provides valuable pharmacokinetic data for sulbactam/ampicillin (SBT/ABPC) in pediatric populations.
- Demonstrates the clinical effectiveness and safety of SBT/ABPC for treating common pediatric bacterial infections.
- Supports the use of SBT/ABPC as a therapeutic option in pediatric infectious disease management.
Abstract:
We have carried out laboratory and clinical studies on sulbactam/ampicillin (SBT/ABPC). The results are summarized as follows. SBT/ABPC was given by 30-minute drip infusion to 1 child at a single dose of 15 mg/kg and to 2 children at a single dose of 30 mg/kg. After the 30-minute drip infusion, peak serum levels of ABPC(SBT) obtained for the 2 dose levels were 18.0 micrograms/ml (12.4 micrograms/ml) for the former dose level and 81.0 micrograms/ml (53.7 micrograms/ml) and 300 micrograms/ml (200 micrograms/ml) for the latter at the end of injection, and half-lives were 0.84 hour (0.82 hour) for the former and 0.96 hour (1.44 hours) and 0.93 hour (1.19 hours) for the latter. In another trial, SBT/ABPC was given to 1 child at a single dose of 60 mg/kg. After the 30-minute drip infusion, peak serum level of ABPC (SBT) was 82.3 micrograms/ml (45.9 micrograms/ml), and half-life was 1.20 hours (1.36 hours). The urinary excretion rates of ABPC (SBT) were 51.3% (49.5%), 55.8 +/- 10.4% (65.3 +/- 9.1%), 74.0% (76.1%) up to 6 hours after the 30-minute drip infusion of 15 mg/kg, 30 mg/kg and 60 mg/kg, respectively. Treatment with SBT/ABPC was made in 21 cases of pediatric bacterial infections: 8 cases of tonsillitis, 4 cases of bronchitis, 3 cases of pneumonia and 1 case each of pharyngitis, peritonsillar abscess, lymphadenitis, impetigo, abscess and urinary tract infection. Results obtained were excellent in 14 cases, good in 7 cases. No significant side effect due to the drug was observed in any cases except 1 case of fever and rash.